Based on a new mass spectrometry system, body fluid samples were analyzed to verify the role of metabolite analysis in the diagnosis of pediatric medulloblastoma.

Screening specific molecular metabolic markers for medulloblastoma after radiotherapy can improve the prediction of clinical diagnosis and prognosis of patients.The purpose of this study is to validate the role of metabolite analysis in the diagnosis of pediatric medulloblastoma based on the analysis of body fluid samples by a new mass spectrometry system.Based on the metabolic markers found by screening, the pathogenic mechanism of metabolic pathway blockade was explained, and the scientific basis for later treatment was put forward.

Inclusion Criteria:

• The samples are previous biological sample database data;
• Sample collection time was 2017.05-2019.05;
• The patient's age is over 3 years old;
• KPS score ≥50 at the first diagnosis;
• The patient was a medulloblastoma patient who had received surgical treatment and had not received radiotherapy or chemotherapy before.

Exclusion Criteria:

• Recurrent patients;
• Patients suffered from other malignant tumors during radiotherapy;
• The body fluid samples or related clinical data are not perfect;
• Storage failure of body fluid samples such as lipid dissolution and hemolysis occurred.

Different body fluid samples (blood,urine)of patients in each group are estimated to be 100 cases.